Want to see HK:1011 full AI Analyst Report?
Top Page
China NT Pharma Group Co., Ltd.
(1011)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.24
â–¼(-72.02% Downside)
Action:Reiterated
Date:10/16/26
The score is driven primarily by weak financial performance—persistent heavy losses, negative equity with high leverage, and renewed cash burn—indicating elevated solvency and funding risk. Technicals add downside pressure as the stock trades below key moving averages with bearish momentum. Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Revenue rebound
The renewed revenue growth indicates that the company regained commercial traction after several weaker years. If this rebound persists, a larger sales base could support better fixed-cost absorption and provide a platform for restoring operating performance over the next several quarters.
Negative Factors
Persistent unprofitability
Persistent net losses and deeply negative operating profitability show that the recent revenue recovery has not yet translated into a sustainable earnings model. Continued losses can consume capital, limit reinvestment, and make future improvement dependent on substantial cost reduction or stronger sales execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The renewed revenue growth indicates that the company regained commercial traction after several weaker years. If this rebound persists, a larger sales base could support better fixed-cost absorption and provide a platform for restoring operating performance over the next several quarters.
Read all positive factors
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$440.16M
Dividend Yield0.02%
Average Volume (3M)165.10K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth100.34%
EPS Growth83.97%
CountryHK
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,796,563,600
10 Day Avg. Volume156,305
30 Day Avg. Volume165,101
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-1.66
Price to Sales (P/S)18.81
P/FCF Ratio-18.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
Company Description
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of ...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products. Revenue is generally generated through (1) sales of proprietary/branded drugs and other drug products that the company manufactures and/or commercializes, recognized when produc...
China NT Pharma Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
9
Very Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.50M | 24.16M | 37.96M | 7.37M | 207.09M | 226.70M |
| Gross Profit | 5.84M | 9.61M | 5.26M | 7.37M | 125.29M | 145.46M |
| EBITDA | -12.90M | -11.72M | -12.57M | 1.33M | 10.39M | -17.78M |
| Net Income | -27.31M | -26.04M | -53.36M | -143.59M | -66.41M | -149.54M |
Balance Sheet | ||||||
| Total Assets | 642.73M | 347.50M | 334.07M | 329.12M | 1.01B | 955.36M |
| Cash, Cash Equivalents and Short-Term Investments | 11.91M | 7.22M | 9.62M | 1.52M | 5.93M | 9.44M |
| Total Debt | 334.93M | 316.83M | 375.95M | 344.94M | 826.45M | 832.11M |
| Total Liabilities | 694.02M | 621.45M | 733.18M | 668.69M | 1.25B | 1.17B |
| Stockholders Equity | -111.24M | -273.74M | -399.11M | -339.56M | -241.66M | -211.38M |
Cash Flow | ||||||
| Free Cash Flow | -19.82M | -24.71M | -9.24M | 37.58M | 31.72M | -135.42M |
| Operating Cash Flow | -19.66M | -24.55M | -9.07M | 50.48M | 36.21M | -134.78M |
| Investing Cash Flow | -581.88K | -154.88K | -189.00K | -22.14M | 4.53M | 257.81M |
| Financing Cash Flow | 29.46M | 24.05M | 12.65M | -28.97M | -46.68M | -124.80M |
China NT Pharma Group Co., Ltd. Technical Analysis
Negative
0.84
Price Trends
0.37
Negative
0.38
Negative
0.54
Negative
Market Momentum
-0.04
Positive
25.78
Positive
11.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Negative. The current price of 0.84 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.37, and above the 200-day MA of 0.54, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 25.78 is Positive, neither overbought nor oversold. The STOCH value of 11.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1011.
China NT Pharma Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$5.67B | 6.07 | 9.81% | 16.66% | -17.74% | 1.12% | |
77 Outperform | HK$774.43M | 7.77 | 13.59% | 7.44% | 10.63% | 39.44% | |
59 Neutral | HK$1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% | |
53 Neutral | HK$401.18M | 100.00 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$123.04M | -4.04 | -21.66% | 0.48% | -6.71% | 43.14% | |
42 Neutral | HK$440.16M | -5.84 | 14.19% | 0.02% | 100.34% | 83.97% |
* Healthcare Sector Average
HK:1011
China NT Pharma Group Co., Ltd.
0.25
-0.54
-68.59%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.36
-0.10
-21.74%
HK:1498
PuraPharm Corp. Ltd.
0.23
-0.19
-45.24%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
0.92
-0.20
-17.86%
HK:0239
Pak Fah Yeow International Limited
2.49
0.25
11.09%
HK:2877
China Shineway Pharmaceutical Group Limited
7.51
1.13
17.67%
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma Challenges RMB92m Arbitral Award and Seeks Exit from Beijing Kangchen Stake
Oct 30, 2026
China NT Pharma Group has disclosed new legal moves tied to its Miacalcic asset transaction with Beijing Konruns Pharmaceutical and its minority stake in Beijing Kangchen Biological Technology. NT Pharma Pacific currently owns around 25.3% of Beij...
China NT Pharma boosts capital structure as it pivots to AI-led bone health platform
Oct 30, 2026
China NT Pharma Group Company Limited is reshaping its healthcare and pharmaceutical business around an AI-driven health management platform for bone health, combining testing, treatment and rehabilitation to create a more integrated industry chai...
China NT Pharma weighs disposal of major Beijing Kangchen stake to fund high-tech pivot
Oct 23, 2026
China NT Pharma Group has disclosed supplemental information on its significant investment holdings, revealing that as of 31 December 2025 its financial assets at fair value through profit or loss totaled about RMB331 million. This amount, represe...
China NT Pharma Calls Extraordinary Meeting to Appoint New Auditor
Oct 20, 2026
China NT Pharma Group has called an extraordinary general meeting in Hong Kong on 9 November 2026 for shareholders to vote on the appointment of HLB Hodgson Impey Cheng Limited as the company’s new auditor. The mandate, if approved, will run...
China NT Pharma Pursues Court Enforcement in Shareholder Information Dispute Over Kangchen Biological
Sep 25, 2026
China NT Pharma says its subsidiary NT Pharma Pacific has been blocked from exercising shareholder information and governance rights at Beijing Kangchen Biological by the Konruns-related shareholders after performance guarantees tied to the Miacal...
China NT Pharma Faces RMB75 Million Arbitration Award Over Miacalcic Deal
Sep 25, 2026
China NT Pharma Group has disclosed that it received an arbitral award from the China International Economic and Trade Arbitration Commission related to a 2020 Miacalcic assets transaction with Beijing Konruns Pharmaceutical. The dispute concerns ...
China NT Pharma Names HLB as New Auditor After Shareholder Rebuff
Sep 14, 2026
China NT Pharma Group Co., Ltd., a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong, focuses on developing and distributing medicines in the Chinese healthcare market through its subsidiaries. The company’s adherence to H...
China NT Pharma Completes Loan Capitalisation Via Major Share Subscription
Sep 4, 2026
China NT Pharma Group has completed a connected transaction to capitalise outstanding loans through the subscription of new shares under a specific mandate. On 4 September 2026, the company issued 847,565,892 new shares at HK$0.365 each, with the ...
China NT Pharma Overhauls Key Company Secretary and Compliance Roles
Aug 31, 2026
China NT Pharma Group has announced the resignation of company secretary and authorised representative Ms. Li Yifang, who also served as the firm’s Hong Kong process agent, effective 31 August 2026. The board noted that Ms. Li leaves without...
China NT Pharma Wins Share Issue Mandate but Loses Auditor Vote at EGM
Aug 28, 2026
Shareholders of China NT Pharma Group Co., Ltd. met in an extraordinary general meeting in Hong Kong on 28 August 2026 to vote on financing and governance matters. Certain interested shareholders, including subscribers to new share issues and part...
NT Pharma Revenue Nearly Doubles but Interim Losses Persist
Aug 20, 2026
China NT Pharma Group Co., Ltd., listed in Hong Kong and incorporated in the Cayman Islands, operates as a pharmaceutical and healthcare services group in mainland China. Its revenue is derived from service-based offerings, positioning the company...
China NT Pharma Faces RMB92 Million Arbitration Award Over 2020 Asset Deal
Aug 18, 2026
China NT Pharma Group Company Limited has received an arbitration award from the China International Economic and Trade Arbitration Commission related to guarantee arrangements under a 2020 asset transaction with Beijing Konruns Pharmaceutical. Th...
China NT Pharma Seeks Shareholder Approval for Major Debt-to-Equity Share Subscriptions
Aug 10, 2026
China NT Pharma Group Company Limited has called an extraordinary general meeting in Hong Kong on 28 August 2026 for shareholders to vote on multiple share subscription arrangements with a group of corporate and individual subscribers, including r...
China NT Pharma Schedules Board Meeting to Review Interim Results and Dividend
Aug 10, 2026
China NT Pharma Group Co., Ltd., a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong, oversees its operations through a board comprising executive, non-executive, and independent non-executive directors. The group focuses on d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.